Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 7.8% in June

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the target of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 75,400 shares, a drop of 7.8% from the May 31st total of 81,800 shares. Based on an average daily volume of 653,500 shares, the short-interest ratio is currently 0.1 days.

Avalo Therapeutics Stock Down 2.8 %

AVTX traded down $0.35 during trading hours on Tuesday, reaching $12.26. The company’s stock had a trading volume of 4,204 shares, compared to its average volume of 356,995. The company’s 50-day moving average is $12.32 and its 200-day moving average is $9.53. Avalo Therapeutics has a 52 week low of $3.95 and a 52 week high of $95.52.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Monday, May 13th. The company reported ($5.98) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($4.80). Avalo Therapeutics had a negative net margin of 1,639.50% and a negative return on equity of 1,439.87%. As a group, research analysts expect that Avalo Therapeutics will post -0.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer raised Avalo Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, April 16th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AVTX. Acadian Asset Management LLC bought a new stake in shares of Avalo Therapeutics during the third quarter worth approximately $34,000. Affinity Asset Advisors LLC acquired a new stake in Avalo Therapeutics during the 1st quarter worth approximately $218,000. Finally, Ikarian Capital LLC bought a new stake in Avalo Therapeutics in the 1st quarter valued at $1,015,000. 87.06% of the stock is owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.